


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-0.31%
-0.08%
-0.10%
-4.04%
BEAM
Beam Therapeutics In
$30.95
Strengths

Trading below its fair value

Upgraded on attractively valued

Investors confidence is positive

Earnings are forecast to grow
BEAM Price Performance
$27.98 (+10.61%)
$24.77 (+24.95%)
$16.31 (+89.76%)
$26.57 (+16.48%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive
Future
Future

Trading below its fair value

Earnings are forecast to grow
![]()
BEAM Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
BEAM Street Sentiment is extremely bullish and have negative views on the near-term outlook
BEAM has Extreme risk level
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
What is BEAM current stock price?
What are BEAM stock strengths?
What is BEAM Risk Level?
What is BEAM market cap and volume?
What is BEAM current Stock IQ?
Should I buy BEAM stock right now?
Is BEAM a Strong Buy right now?
What does a 'Strong Buy' rating mean for BEAM?
What does a 'Strong Sell' rating mean for BEAM?
What factors influence BEAM's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-0.31%
-0.08%
-0.10%
-4.04%
BEAM
Beam Therapeutics In
Current Price
$30.95
Stock Insights
Strengths

Trading below its fair value

Upgraded on attractively valued

Investors confidence is positive

Earnings are forecast to grow

BEAM Price Performance
$27.98 (+10.61%)
$24.77 (+24.95%)
$16.31 (+89.76%)
$26.57 (+16.48%)
BEAM Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive
Future
Future

Trading below its fair value

Earnings are forecast to grow
![]()
BEAM Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
BEAM Street Sentiment is extremely bullish and have negative views on the near-term outlook
BEAM has Extreme risk level
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Nov 25, 2025
Initiate
Outperform
Evercore ISI
Oct 10, 2025
Reiterate
Buy
HC Wainwright & Co.
BEAM Stock IQ
BEAM Latest Analysis
Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.
Wed Jan 14, 2026
BEAM Outlines Key Strategic & Pipeline Goals for 2026 Stock Rises. Beam Therapeutics jumps 22% after outlining 2026 pipeline goals including accelerated approval plans for BEAM-302 and a potential risto-cel BLA filing.
Tue Jan 13, 2026
Beam Therapeutics Stock Surges: Whats Driving The Sudden Jump?. BEAM).Beam Therapeutics shares are climbing with conviction. Beam has reported progress with the FDA on a potential accelerated approval path for BEAM‑302 and plans to file a Biologics License Application (BLA) for risto‑cel as early as the end of 2026. Beam said it has reached alignment with the FDA on a potential accelerated approval pathway for BEAM‑302 using biomarker ...
Mon Jan 12, 2026
Beam Therapeutics shares jump on progress in precision genetic medicines and 2026 strategic plans.
Mon Jan 12, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
BEAM Stock trends
BEAM Stock performance
BEAM Stock analysis
BEAM investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.